OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales

April 25, 2016 11:48am EDT

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. (NYSE: OPK )

today announced the appointment of James DeMarco as Senior Vice

President of Pharmaceutical Sales to support the anticipated launch of

RAYALDEE ® .

Mr. DeMarco has over 30 years of commercial pharmaceutical experience

with established large companies, such as Schering Plough, Amgen and

Eisai, as well as emerging companies, and a career-long focus on

specialty products and nephrology. Prior to joining OPKO, Mr. DeMarco

served as a consultant providing commercial leadership services to

pharmaceutical, medical device and healthcare services companies. Mr.

DeMarco has built a number of sales organizations during his career in

advance of anticipated product launches in a diverse group of

therapeutic areas.

“Jim is uniquely qualified to establish and execute our commercial plans

for RAYALDEE in the US. His deep knowledge of the chronic kidney disease

market will help bring RAYALDEE to Stage 3 and 4 CKD patients,” said

Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. Dr.

Frost continued, “We look forward to rapidly moving through the final

regulatory steps with the FDA and securing an approval.”

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to

establish industry-leading positions in large, rapidly growing markets.

Our diagnostics business includes Bio-Reference Laboratories, the

nation's third-largest clinical laboratory with a core genetic testing

business and a 420-person sales force to drive growth and leverage new

products, including the 4Kscore® prostate cancer test and the Claros®1

in-office immunoassay platform. Our pharmaceutical business features

Rayaldee ® , a treatment for SHPT in stage 3-4 CKD patients

with vitamin D insufficiency and VARUBI™ for chemotherapy-induced nausea

and vomiting (oral formulation launched by partner Tesaro, IV

formulation in Phase 3). Our biologics business includes hGH-CTP, a

once-weekly human growth hormone injection (in Phase 3 and partnered

with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase

2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase

1). We also have production and distribution assets worldwide, multiple

strategic investments and an active business development strategy. More

information is available at www.opko.com .

This press release contains "forward-looking statements," as that

term is defined under the Private Securities Litigation Reform Act of

1995 (PSLRA), which statements may be identified by words such as

"expects," "plans," "projects," "will," "may," "anticipates,"

"believes," "should," "intends," "estimates," and other words of similar

meaning, including all non-historical statements about our expectations,

beliefs or intentions regarding our business, technologies and products,

financial condition, strategies, prospects, growth opportunities, and

management. Many factors could cause our actual activities or results to

differ materially from the activities and results anticipated in

forward-looking statements. These factors include those described in our

filings with the Securities and Exchange Commission, and risks inherent

in funding, developing and obtaining regulatory approvals of new,

commercially-viable and competitive products and treatments. In

addition, forward-looking statements may also be adversely affected by

general market factors, competitive product development, product

availability, federal and state regulations and legislation, the

regulatory process for new products and indications, manufacturing

issues that may arise, patent positions and litigation, among other

factors. The forward-looking statements contained in this press release

speak only as of the date the statements were made, and, except as

required by applicable law, we do not undertake any obligation to update

forward-looking statements. We intend that all forward-looking

statements be subject to the safe-harbor provisions of the PSLRA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160425006107/en/

OPKO Health, Inc.

Tara Mackay, 305-575-4100

Investor

Relations

or

Media

Rooney & Associates

Terry

Rooney, 212-223-0689

or

Marion

Janic, 212-223-4017

or

Investors

LHA

Anne

Marie Fields, 212-838-3777

or

Bruce

Voss, 310-691-7100

Source: OPKO Health, Inc.

Released April 25, 2016

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap